NASDAQ:IMAB - Nasdaq - US44975P1030 - ADR - Currency: USD
0.97
+0 (+0.34%)
The current stock price of IMAB is 0.97 USD. In the past month the price decreased by -8.49%. In the past year, price decreased by -40.85%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 220 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
I-MAB-SPONSORED ADR
Suite 400, 2440 Research Blvd
Rockville MARYLAND 201210 US
CEO: Joan Huaqiong Shen
Employees: 220
Company Website: https://www.i-mabbiopharma.com/
Investor Relations: https://ir.i-mabbiopharma.com/
Phone: 13016702800
The current stock price of IMAB is 0.97 USD. The price increased by 0.34% in the last trading session.
The exchange symbol of I-MAB-SPONSORED ADR is IMAB and it is listed on the Nasdaq exchange.
IMAB stock is listed on the Nasdaq exchange.
9 analysts have analysed IMAB and the average price target is 5.78 USD. This implies a price increase of 495.88% is expected in the next year compared to the current price of 0.97. Check the I-MAB-SPONSORED ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
I-MAB-SPONSORED ADR (IMAB) has a market capitalization of 78.46M USD. This makes IMAB a Micro Cap stock.
I-MAB-SPONSORED ADR (IMAB) currently has 220 employees.
I-MAB-SPONSORED ADR (IMAB) has a support level at 0.97 and a resistance level at 1.05. Check the full technical report for a detailed analysis of IMAB support and resistance levels.
The Revenue of I-MAB-SPONSORED ADR (IMAB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the IMAB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IMAB does not pay a dividend.
I-MAB-SPONSORED ADR (IMAB) will report earnings on 2025-03-13, after the market close.
I-MAB-SPONSORED ADR (IMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.12).
The outstanding short interest for I-MAB-SPONSORED ADR (IMAB) is 3.13% of its float. Check the ownership tab for more information on the IMAB short interest.
ChartMill assigns a fundamental rating of 2 / 10 to IMAB. IMAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months IMAB reported a non-GAAP Earnings per Share(EPS) of -18.12. The EPS increased by 45.59% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -56.09% | ||
ROE | -85.31% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 84% to IMAB. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 92.19% and a revenue growth -100% for IMAB